Clinical trial
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and…
NCT00478634 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00478634 |
|---|---|
| Title | A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer |
| Official title | An Open-label, Multicenter Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab (if Given as Part of Local Standard Practice) in Patient With Metastatic Colorectal Adenocarcinoma |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal |
| Intervention type | Drug |
| Interventions | RAD001, Cetuximab, Irinotecan |
| Enrollment | 19 |
| Start date | May 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | May 25, 2007 |
| Last update posted | Nov 2, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: